NIH News Releases

Tecovirimat is safe but ineffective as treatment for clade II mpox

NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions.

Mar 12, 2025 - 19:08
 0
Tecovirimat is safe but ineffective as treatment for clade II mpox
NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions.
Read More

Tags:

Previous Article

Balance of power: why Loch Ness hydro storage schemes are fuelling anxiety

Next Article

Captain D’s to open first U.K. location in summer 2025

Related Posts

NIH-funded clinical trial will evaluate new dengue therapeutic

NIH-funded clinical trial will evaluate new dengue ther...

Feb 11, 2025  0

NIH to lead implementation of National Plan to End Parkinson’s Act

NIH to lead implementation of National Plan to End Park...

Feb 9, 2025  0

Influenza A viruses adapt shape in response to environmental pressures

Influenza A viruses adapt shape in response to environm...

Feb 10, 2025  0